Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial

作者：BJ Manley, COF Kamlin, Susan Donath, KL Francis, JLY Cheong, PA Dargaville, Jennifer A. Dawson, SE Jacobs, Paul R. J. Birch, SM Resnick, Georg M. Schmölzer, B Law, Risha Bhatia, Kathryn Bach, Koert de Waal, Javeed Travadi, PJ Koorts, Mark J. Berry, Kei Lui, VS Rajadurai, Suresh Chandran, Martin Kluckow, Elza Cloete, MM Broom, Michael J. Stark, Adrienne Gordon, Vinayak Kodur, Lex W. Doyle, PG Davis, CJD McKinlay, for the PLUSS Trial Investigator · 发表于：Obstetric Anesthesia Digest · 年份：2025 · DOI：10.1097/01.aoa.0001125496.34348.95 · 被引用次数：5 · 研究领域：Airway Management and Intubation Techniques、Neonatal Respiratory Health Research、Respiratory Support and Mechanisms

( JAMA . 2024;332(22):1889–1899. DOI: 10.1001/jama.2024.17380) Bronchopulmonary dysplasia (BPD) is a frequent and serious condition that affects extremely preterm infants, particularly those born before 28 weeks of gestation. While systemic corticosteroids are known to be effective in minimizing BPD, they carry a risk of adverse side effects. Intratracheal corticosteroids, which are administered directly into the lungs with surfactant, could offer a safer and potentially effective alternative. This study aimed to evaluate the effectiveness of early administration of intratracheal corticosteroids in preventing BPD and improving survival in extremely preterm infants.